PROSPECTUS SUPPLEMENT NO. 1
|
Filed Pursuant to Rule 424(b)(3)
|
(to Prospectus dated October 26, 2021)
|
Registration No. 333-260306
|
Jasper Therapeutics, Inc.
33,081,493 Shares of Voting Common Stock
Up to 5,000,000 shares of Voting Common Stock Issuable Upon
Exercise of Warrants
This prospectus supplement supplements the prospectus,
dated October 26, 2021 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-260306).
This prospectus supplement is being filed to update and supplement the information in the Prospectus with the information in our Current
Report on Form 8-K filed with the Securities and Exchange Commission on October 29, 2021 (the “Form 8-K”). Accordingly, we
have attached the Form 8-K to this prospectus supplement.
The Prospectus and this prospectus supplement relates
to: (i) the resale by the investors listed in the section of the Prospectus entitled “Selling Stockholders” (the “Selling
Stockholders”) of up to 33,081,493 shares (the “Resale Shares”) of our voting common stock, par value $0.0001 per
share (“Common Stock”), and (ii) the issuance by us and the resale of up to 5,000,000 shares of Common Stock upon the
exercise of outstanding warrants (the “Public Warrants”). The Resale Shares consist of: (a) 2,300,000 shares of Common
Stock held by Amplitude Healthcare Holdings LLC (the “Sponsor”) that were issued upon conversion on September 24, 2021
of 2,300,000 shares of our former Class B Common Stock in connection with the business combination (the “Business Combination”)
pursuant to that certain Business Combination Agreement, dated May 5, 2021, by and among us, Ample Merger Sub, Inc., our then-wholly
owned subsidiary, and the pre-Business Combination Jasper Therapeutics, Inc. (now named Jasper Tx Corp.), that were previously issued
to the Sponsor on August 23, 2019 in a private placement to the Sponsor; (b) 19,485,471 shares of Common Stock issued to certain
of the Selling Stockholders on September 24, 2021 in connection with the Business Combination; (c) up to 1,296,022 shares of
Common Stock issuable upon conversion of 1,296,022 shares of our non-voting common stock, par value $0.0001 per share (issued to a Selling
Stockholder on September 24, 2021 in connection with the Business Combination; and (d) 10,000,000 shares of Common Stock issued
on September 24, 2021 in a private placement in connection with the closing of the Business Combination pursuant to those certain
subscription agreements, dated May 5, 2021 between us and certain of the Selling Stockholders.
This prospectus supplement updates and supplements
the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus,
including any amendments or supplements thereto. This prospectus supplement should be read in conjunction with the Prospectus, including
any amendments or supplements thereto, which is to be delivered with this prospectus supplement. This prospectus supplement is qualified
by reference to the Prospectus, including any amendments or supplements thereto, except to the extent that the information in this prospectus
supplement updates and supersedes the information contained therein.
Our Common Stock is listed on the Nasdaq Capital
Market under the symbol “JSPR”. On October 28, 2021, the last reported sales price per share of our Common Stock was $8.88.
Our Public Warrants are listed on the Nasdaq Capital Market under the symbol “JSPRW.” On October 28, 2021, the closing
sale price per warrant of our Public Warrants was $1.27.
We are an “emerging growth company”
as that term is used in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) and, as such, we have elected to
comply with certain reduced public company reporting requirements for this prospectus and future filings with the Securities and Exchange
Commission.
Investing in our Common Stock involves substantial
risk. You should review carefully the risks and uncertainties described under the heading “Risk Factors” beginning on page
7 of the Prospectus.
Neither the Securities and Exchange Commission
nor any other regulatory body has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus
supplement. Any representation to the contrary is a criminal offense.
The date of this prospectus supplement is October
29, 2021.
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of Earliest Event Reported): October 25, 2021
JASPER
THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-39138
|
|
84-2984849
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.)
|
2200 Bridge Pkwy Suite #102
Redwood City, CA
|
|
94065
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(650)
549-1400
Registrant’s
telephone number, including area code
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which
registered
|
Voting Common Stock,
par value $0.0001 per share
|
|
JSPR
|
|
The
Nasdaq Stock Market LLC
|
Redeemable Warrants,
each whole warrant exercisable for one share of Voting Common Stock at an exercise price of $11.50
|
|
JSPRW
|
|
The
Nasdaq Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2
of the Securities Exchange Act of 1934.
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
On
October 25, 2021, the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) adopted a
non-employee director compensation policy (the “Non-Employee Director Compensation Policy”). Pursuant to the Non-Employee
Director Compensation Policy, each non-employee director is eligible to receive annual cash retainers for his or her service on the Board
and the Board’s committees, as follows:
|
|
Annual
Retainer
|
|
Board of Directors (including Chairperson)
|
|
$
|
40,000
|
|
Board of Directors Chairperson
|
|
$
|
30,000
|
|
Audit Committee Chairperson
|
|
$
|
15,000
|
|
Audit Committee Member (excluding Chairperson)
|
|
$
|
7,500
|
|
Compensation Committee Chairperson
|
|
$
|
10,000
|
|
Compensation Committee Member (excluding Chairperson)
|
|
$
|
5,000
|
|
Nominating and Corporate Governance Committee Chairperson
|
|
$
|
8,000
|
|
Nominating and Corporate Governance Committee Member (excluding Chairperson)
|
|
$
|
4,000
|
|
All
cash retainers will be earned on a quarterly basis based on a calendar quarter, and, if applicable, will be prorated for the portion
of the calendar quarter during which such non-employee director actually serves on the Board or a committee thereof, and will be paid
in arrears no later than the 30th day following the end of each calendar quarter.
The
Non-Employee Director Compensation Policy also provides that the Company will reimburse reasonable expenses incurred by the non-employee
directors in connection with attendance at Board or committee meetings.
In
addition to cash fees, each current non-employee director will be granted a one-time stock option award to purchase a number of shares
of voting common stock of the Company (“Common Stock”) equal to 0.10% of the total number of shares of capital stock of the
Company outstanding on an as-converted to Common Stock basis on the date of grant, which will vest in three equal annual installments
over three years, subject to the director’s continued service through such vesting dates. These grants will be made to the Company’s
current non-employee directors as soon as administratively practicable following the effectiveness of the filing with the Securities
and Exchange Commission of the first Registration Statement on Form S-8 covering shares of Common Stock issuable pursuant to the Company’s
2021 Equity Incentive Plan (as may be amended or restated, the “2021 Plan”). Moreover, any new non-employee elected or appointed
to the Board will, upon his or her appointment to the Board, be granted a one-time stock option award to purchase a number of shares
of Common Stock equal to 0.10% of the total number of shares of capital stock of the Company outstanding on an as-converted to Common
Stock basis on the date of grant, which will vest in three equal annual installments over three years, subject to the director’s
continued service through such vesting dates.
The
Non-Employee Director Compensation Policy also provides that, on the date of each annual meeting of stockholders of the Company (each,
an “Annual Meeting”), each individual who is a non-employee director immediately prior to such Annual Meeting and who will
continue to serve as a non-employee director immediately following such Annual Meeting will be granted an annual stock option award to
purchase a number of shares of Common Stock equal to 0.05% of the total number of shares of capital stock of the Company outstanding
on an as-converted to Common Stock basis on the date of grant, which will vest in full upon the first anniversary of the date of the
grant, subject to the director’s continued service through such vesting date.
In
addition, each of the stock option awards granted pursuant to the Non-Employee Director Compensation Policy will vest in full as of immediately
prior to, and contingent upon, the occurrence of a Change in Control (as defined in the 2021 Plan), subject to the director’s continued
service through immediately prior to such Change in Control.
The
foregoing description of the Non-Employee Director Compensation Policy does not purport to be complete and is qualified in its entirety
by the terms and conditions of the Non-Employee Director Compensation Policy, which is attached hereto as Exhibit 10.1 and incorporated
herein by reference.
Item
9.01. Financial Statements and Exhibits.
(d) Exhibits.
|
+
|
Indicates
a management contract or compensatory plan.
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.
|
JASPER
THERAPEUTICS, INC.
|
|
|
|
Date: October 29, 2021
|
By:
|
/s/
Jeet Mahal
|
|
|
Name:
|
Jeet Mahal
|
|
|
Title:
|
Chief Financial Officer and
Chief
Business Officer
|
Exhibit
10.1
JASPER
Therapeutics, INC.
NON-EMPLOYEE
DIRECTOR COMPENSATION POLICY
Each
non-employee member of the board of directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”)
shall be eligible to receive cash and equity compensation for his or her service on the Board as set forth in this Non-Employee Director
Compensation Policy (this “Policy”). The cash and equity compensation described in this Policy shall be paid
or be made, as applicable, automatically and without further action of the Board (or any committee thereof), to each member of the Board
who is not an employee of the Company or any parent or subsidiary of the Company (each, a “Non-Employee Director”)
who is eligible to receive such cash or equity compensation, unless such Non-Employee Director declines the receipt of such cash or equity
compensation by advance written notice to the Company. This Policy shall remain in effect until it is revised or rescinded by further
action of the Board or the Compensation Committee of the Board (the “Compensation Committee”). This Policy
and the compensation to be provided hereunder may be amended, modified or terminated by the Board or the Compensation Committee at any
time in its sole discretion. The terms and conditions of this Policy shall supersede any prior cash and/or equity compensation arrangements
between the Company and any of its Non-Employee Directors with respect to such Non-Employee Director’s service on (or on behalf
of) the Board or any committee thereof. No Non-Employee Director shall have any rights hereunder, except with respect to the cash compensation
and stock options granted pursuant to this Policy. Non-Employee Directors may be eligible to receive discretionary awards granted outside
this Policy.
(a)
Annual Cash Retainers. Each Non-Employee Director shall be eligible to receive an annual cash retainer of $40,000 for service
on the Board.
(b)
Additional Annual Cash Retainers. In addition, a Non-Employee Director shall receive the following annual cash retainers, if applicable:
(i)
Chairperson of the Board. A Non-Employee Director serving as Chairperson of the Board shall receive an additional annual cash
retainer of $30,000 for such service.
(ii)
Audit Committee. A Non-Employee Director serving as Chairperson of the Audit Committee of the Board (the “Audit Committee”)
shall receive an additional annual cash retainer of $15,000 for such service. A Non-Employee Director serving as a member of the Audit
Committee (other than the Chairperson) shall receive an additional annual cash retainer of $7,500 for such service.
(iii)
Compensation Committee. A Non-Employee Director serving as Chairperson of the Compensation Committee shall receive an additional
annual cash retainer of $10,000 for such service. A Non-Employee Director serving as a member of the Compensation Committee (other than
the Chairperson) shall receive an additional annual cash retainer of $5,000 for such service.
(iv)
Nominating and Corporate Governance Committee. A Non-Employee Director serving as Chairperson of the Nominating and Corporate
Governance Committee of the Board (the “Nominating and Corporate Governance Committee”) shall receive an additional
annual cash retainer of $8,000 for such service. A Non-Employee Director serving as a member of the Nominating and Corporate Governance
Committee (other than the Chairperson) shall receive an additional annual cash retainer of $4,000 for such service.
(c)
Payment of Retainers. The annual cash retainers described in Sections 1(a) and 1(b) shall be earned on a quarterly basis based
on a calendar quarter and shall be paid by the Company in arrears not later than the 30th day following the end of each calendar quarter.
In the event a Non-Employee Director does not serve as a Non-Employee Director, or in the applicable positions described in Section 1(b),
for an entire calendar quarter, the retainer paid to such Non-Employee Director shall be prorated for the portion of such calendar quarter
actually served as a Non-Employee Director, or in such position, as applicable. For avoidance of doubt, if a Non-Employee Director serves
on the Board or a committee thereof for less than a full calendar quarter, the annual cash retainers described in Sections 1(a) and 1(b)
shall be prorated for the portion of the calendar quarter in which the Non-Employee Director began serving on the Board or a committee
thereof, as applicable, such that each Non-Employee Director shall receive annual cash retainers under this Policy only for the periods
during which such Non-Employee Director actually serves on the Board or a committee thereof, as applicable. The annual cash retainers
for Non-Employee Directors serving as of the date of adoption of this Policy shall be payable retroactively on a pro rata basis from
September 24, 2021, with the payment for service on the Board between September 24, 2021 to September 30, 2021 to be made concurrently
with the payment of the cash retainers for the quarter ending December 31, 2021. There are no per meeting attendance fees for attending
meetings of the Board or any committee thereof.
(d)
Revisions. Each of the Board and the Compensation Committee, in its discretion, may change and otherwise revise the terms of the
cash compensation granted under this Policy, including, without limitation, the amount of cash compensation to be paid, on or after the
date the Board or the Compensation Committee determines to make any such change or revision.
Non-Employee Directors shall be granted the equity awards described below. The awards described below shall
be granted under and shall be subject to the terms and provisions of the Company’s 2021 Equity Incentive Plan, as may be amended
or restated from time to time, or any other applicable Company equity incentive plan then-maintained by the Company (the “Equity
Plan”), and shall be granted subject to the execution and delivery of award agreements, including attached exhibits, in
substantially the forms previously approved by the Board or the Compensation Committee, setting forth the vesting schedule applicable
to such awards and such other terms as may be required by the Equity Plan (as may be amended or restated from time to time, collectively,
the “Additional Terms”). All applicable terms of the Equity Plan apply to this Policy as if fully set forth
herein, and all stock options granted pursuant to this Policy are subject in all respects to the terms of the Equity Plan and the Additional
Terms.
(a)
Initial Awards for Current Non-Employee Directors. As soon as administratively practicable following the effectiveness of the
filing with the Securities and Exchange Commission of the first registration statement on Form S-8 with respect to the Company’s
2021 Equity Incentive Plan, each Non-Employee Director shall be automatically, and without further action of the Board or the Compensation
Committee, granted a one-time non-statutory stock option to purchase a number of shares of voting common stock of the Company (“Common
Stock”) equal to 0.10% of the total number of shares of capital stock of the Company outstanding on an as-converted to
Common Stock basis on the date of grant. The awards described in this Section 2(a) shall be referred to as “Initial
Awards.”
(b)
Appointment Awards for New Non-Employee Directors. Upon the date an individual first becomes appointed or elected as a Non-Employee
Director, such individual shall be automatically, and without further action of the Board or the Compensation Committee, granted a one-time
non-statutory stock option to purchase a number of shares of Common Stock equal to 0.10% of the total number of shares of capital stock
of the Company outstanding on an as-converted to Common Stock basis on the date of grant. The awards described in this Section 2(b)
shall be referred to as “Appointment Awards.”
(c)
Annual Awards. On the date of each annual meeting of stockholders of the Company (each, an “Annual Meeting”),
each individual who is a Non-Employee Director immediately prior to such Annual Meeting and who will continue to serve as
a Non-Employee Director immediately following such Annual Meeting shall be automatically, and without further action of the Board
or the Compensation Committee, granted a non-statutory stock option to purchase a number of shares of Common Stock equal to 0.05% of
the total number of shares of capital stock of the Company outstanding on an as-converted to Common Stock basis on the date of grant.
The awards described in this Section 2(c) shall be referred to as “Annual Awards.” For
the avoidance of doubt, a Non-Employee Director elected for the first time to the Board at an Annual Meeting shall only receive an Appointment
Award in connection with such election, and shall not receive any Annual Award on the date of such Annual Meeting.
(d)
Termination of Employment of Employee Directors. Members of the Board who are employees of the Company or any parent or subsidiary
of the Company who subsequently terminate their employment with the Company and any parent or subsidiary of the Company and remain on
the Board will not receive an Appointment Award grant pursuant to Section 2(b) above, but to the extent that they are otherwise eligible,
will be eligible to receive, after termination from employment with the Company and any parent or subsidiary of the Company, Annual Awards
as described in Section 2(c) above.
(e)
Terms of Awards Granted to Non-Employee Directors.
(i)
Purchase Price. The per share exercise price of each option granted to a Non-Employee Director shall equal the Fair Market Value
(as defined in the Equity Plan) of a share of Common Stock on the date the option is granted.
(ii)
Vesting. One-third of the shares subject to each Initial Award and each Appointment Award shall vest and become exercisable on
each one-year anniversary of the date of grant, in each case subject to the Non-Employee Director continuing in service on the Board
through and including such vesting date. Each Annual Award shall vest and become exercisable on the one-year anniversary of the date
of grant, in each case subject to the Non-Employee Director continuing in service on the Board through and including such vesting date.
No portion of an Initial Award, Appointment Award or Annual Award that is unvested or unexercisable at the time of a Non-Employee Director’s
termination of service on the Board shall become vested or exercisable thereafter. All Initial Awards, Appointment Awards and Annual
Awards held by a Non-Employee Director shall vest in full as of immediately prior to, and contingent upon, the occurrence of a Change
in Control (as defined in the Equity Plan), subject to such Non-Employee Director’s continuous service with the Company (or a parent
or subsidiary of the Company) through immediately prior to such Change in Control.
(iii)
Term. The term of each stock option granted to a Non-Employee Director shall be ten years from the date the option is granted.
Upon a Non-Employee Director’s termination of service on the Board for any reason, his or her then-vested stock options to purchase
shares of Common Stock granted pursuant to this Policy shall remain exercisable for three months following the termination of his or
her service on the Board (or such longer period as the Board may determine in its discretion on or after the date of grant of such stock
options).
(iv)
Option Award Agreements. Notwithstanding anything to the contrary in this Policy, each Initial Award, Appointment Award and Annual
Award, shall be subject to the terms and conditions of the Equity Plan and the Additional Terms.
(f)
Revisions. Each of the Board and the Compensation Committee, in its discretion, may change and otherwise revise the terms
of awards granted under this Policy, including, without limitation, the types of awards, the number of shares, the exercise prices, and
vesting schedules, for awards granted on or after the date the Board or the Compensation Committee determines to make any such change
or revision.
|
3.
|
Expense Reimbursement.
|
Upon presentation of documentation of such expenses reasonably satisfactory
to the Company, each Non-Employee Director shall be reimbursed for his or her reasonable out-of-pocket business expenses incurred in connection
with attending meetings of the Board and its committees or in connection with other business related to service on the Board or its committees.
Each Non-Employee Director also shall be reimbursed for his or her reasonable out-of-pocket business expenses authorized by the Board
or one of its committees that are incurred in connection with attendance at meetings with the Company’s management. All reimbursements
under this Section 3 shall be made in accordance with the Company’s applicable expense reimbursement policies and procedures as
in effect from time to time.
Adopted
on October 25, 2021
4
Amplitude Healthcare Acq... (NASDAQ:AMHC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amplitude Healthcare Acq... (NASDAQ:AMHC)
Historical Stock Chart
From Apr 2023 to Apr 2024